Characteristics associated with mortality in patients with chronic obstructive pulmonary disease (COPD)–heart failure coexistence

Franciele Plachi1, Fernanda M. Balzan1, Renata A. Sanseverino1, Dora V. Palombini1, Renata D. Marques1,2, Nadine O. Claussell1, Marli M. Knorst1, J. Alberto Neder2 and Danilo C. Berton1,2

1Hospital de Clinicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil and 2Queen’s University & Kingston General Hospital, Kingston, ON, Canada

Abstract

Aim: To investigate if cardiac/pulmonary functional tests and variables obtained from clinical practice (body mass index, dyspnea, functional class, clinical judgment of disability to perform an exercise test and previous hospitalization rate) are related to mortality in patients with overlap chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF).

Background: Although the coexistence of COPD and CHF has been growingly reported, description of survival predictors considering the presence of both conditions is still scarce.

Methods: Using a cohort design, outpatients with the previous diagnosis of COPD and/or CHF that performed both spirometry and echocardiography in the same year were followed-up during a mean of 20.9 ± 8.5 months. Findings: Of the 550 patients initially evaluated, 301 had both spirometry and echocardiography: 160 (53%) with COPD on isolation; 100 (33%) with CHF on isolation; and 41 (14%) with overlap. All groups presented similar mortality: COPD 17/160 (11%); CHF 12/100 (12%); and overlap 7/41 (17%) (P = 0.73). In the overlap group (n = 41), inability to exercise and hospitalization rate were the unique parameters associated with higher mortality (seven events) in univariate analyses. In conclusion, inability to exercise and hospitalization rate emerged as the unique parameters associated with mortality in our sample.

Introduction

Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) are main causes of dyspnea and exercise intolerance, being highly prevalent in the general elderly population (van Mourik et al., 2014). The coexistence of both diseases is common but often unrecognized. Considering the overlap in signs and symptoms, one condition frequently pass unnoticed once the another disease has been previously diagnosed. This was showed by previous studies describing a high prevalence of unknown CHF in COPD (McCullough et al., 2003; Rutten et al., 2005; Beghé et al., 2013) and vice versa (Macchia et al., 2012; Boschetto et al., 2013). Accordingly, additional investigational tools, such as spirometry and echocardiography, are required for an adequate diagnosis.

Beyond the diagnostic challenge, the overlap of COPD and CHF has been associated with increased morbidity, poor quality of life and greater utilization of healthcare resources. Moreover, overlap frequently compounds with other systemic co-morbidities contributing to poor prognosis (Rutten et al., 2005; Macchia et al., 2012).

Despite the interest in the interactions between both diseases has recently grown (Fabbri et al., 2008; Rutten, 2013), description of survival predictors are still scarce (Alencar et al., 2016). While cardiopulmonary exercise testing (CPET)-derived parameters have demonstrated key prognostic significance in patients with COPD (Oga et al., 2003; Neder et al., 2016), CHF (Mancini et al., 1991; Poggio et al., 2010) and both diseases (Alencar et al., 2016), we must acknowledge that overlap patients are usually extremely frail and frequently never become stable enough to perform an exercise test (Arbex et al., 2016).

In COPD, the severity of the baseline disease is closely related to the severity of exacerbations, that is patients with severe disease are more likely to be hospitalized due to an exacerbation. In the long term, patients who experience severe exacerbations have an increased risk of more severe exacerbations in the future (Garcia-Aymerich et al., 2001; Donaldson et al., 2003). The coexistence with cardiac disease may influence the severity of an exacerbation. In fact, COPD patients with cardiac disease present increased risk of hospitalization due to an exacerbation (Miravitlles et al., 2000) and an increased risk of mortality (Antonelli Incalzi et al., 1997; Macchia et al., 2012).
The main objective of the present study, therefore, was to investigate if markers of disease severity obtained from clinical practice (body composition, dyspnea, functional class, inability to perform a clinical exercise test and previous hospitalization rate: Boeck et al., 2016), would be associated with higher risk of mortality beyond cardiac/lung function tests in patients with overlap COPD and CHF. Second, we aim to describe the prevalence and mortality rate of the coexistence of COPD + CHF in outpatient subjects.

**Methods**

**Design**

*Retrospective cohort study*

All patients managed in the COPD and CHF outpatient clinic at our institution presenting both spirometry and echodoppler cardiography during the year of 2014 were included. Their vital status was followed-up until May 2016. All data were obtained from an electronic medical record system [AGHweb®, Hospital de Clínicas de Porto Alegre (HCPA), Brazil], which contains the full medical history of the subjects attended at our institution. Functional parameters, number of hospitalizations within the previous year, clinical assessment and other predictors of the outcome were evaluated at baseline (study inclusion). The study was approved by the Research Ethics Committee (No. 14-0513) and, due to its retrospective nature, the obtention of informed consent was waived.

**Participants**

The main inclusion criteria for COPD were previously established clinical diagnosis, current or previous smoking >10 pack-year, plus spirometric evidence of post-bronchodilator expiratory air-flow obstruction [forced expiratory volume in 1 s (FEV₁)/forced vital capacity (FVC) <0.7] (Vogelmeier et al., 2017). CHF diagnosis was based on presence of Framingham criteria (Ho et al., 1993) plus left ventricular ejection fraction (LVEF) <50% measured by echocardiography. Subjects with both diagnoses (COPD + CHF) comprise the ‘overlap’ group. Charlson comorbidity index was calculated (Charlson et al., 1987), and pulmonary and cardiovascular medication was recorded.

**Measurements**

**Lung function**

Spirometry was obtained (CPF®, Eric Jaeger, GmbH, Würzburg, Germany) according to international standards (Miller et al., 2005).

**Echocardiogram**

Bidimensional transthoracic echocardiogram on M-mode (EnVisor C; Philips, Bothell, WA, USA) was performed according to the American Society of Echocardiography guidelines (Lang et al., 2015).

**Modified Medical Research Council (mMRC) scale**

Patients had to grade their self-perceived dyspnea by using predefined statements ranging from dyspnea only with strenuous exercise (0) to dyspnea to leave the house or when dressing or undressing (4) (Bestall et al., 1999).

**Functional capacity**

It was evaluated by the New York Heart Association (NYHA) scale (Dolgin et al., 1994), a four-level classification based on a patient’s symptoms to perform graded physical activities.

**Hospitalization rate**

The number of hospitalizations due to COPD and/or CHF decompensation was recorded from the year preceding each patient inclusion (Müllerova et al., 2015).

**Inability to perform a CPET**

This parameter was defined by researchers’ agreement (F.P. and D.C.B.) based on the clinical report and related complementary tests at study inclusion considering that the patient would not be able to perform a clinical exercise test for some reason (except social or cognitive).

**Statistical analyses**

Continuous data are presented as mean±SD, while categorical data as number (%). Overlap patients were contrasted by non-paired t or Mann–Whitney’s test or a χ² test for differences in proportions according their vital status at the end of follow-up. Univariate logistic regression analyses were performed to assess parameters at study inclusion [age, body mass index, FEV₁ (% of predicted); FVC (% predicted); FEV₁/FVC ratio; LVEF; mMRC; NYHA functional class; hospitalization rate; and inability to exercise] associated with mortality. The level of statistical significance was set at P<0.05. Receiver-operating characteristics (ROC) curve analysis selected the optimal threshold values for event prediction (MedCalc® for Windows, v.14.12.0, Ostend, Belgium). All remaining statistical analyses were performed using SPSS® statistical package (v.22.0.0.1, Chicago, USA).

**Results**

During the year of baseline assessment for inclusion (2014), 550 patients were evaluated. Of these, 301 had both spirometry and echocardiography: 160 (53%) with COPD on isolation; 100 (33%) with CHF on isolation; and 41 (14%) with overlap COPD plus CHF. The mean follow-up of the present cohort was 20.9±8.5 months, with similar mortality among the groups: COPD 17/160 (11%); CHF 12/100 (12%); and CHF–COPD 7/41 (17%) (P=0.73).

The baseline characteristics of the overlap group was compared according to survival status as presented in Table 1. On average, they presented moderate dyspnea and functional capacity reduction, high prevalence of other co-morbidities and moderate-to-severe reduction in FEV₁ (Vogelmeier et al., 2017).

The proportion of patients with inability to perform a clinical exercise test [4/7 (57%) versus 6/34 (18%); P=0.03] was higher among non-survivors. The main reasons to consider a patient unable to perform an exercise test were: moderate-to-severe dyspnea at rest (n=4); intolerance to walk less than few meters (n=2); excessive lower limb pain (n=2), intolerable exercise angina with clinical optimized treatment and without indication/condition to invasive treatment (n=2). The hospitalization rate also tended to be higher among non-survivors (2.29±1.98 versus 0.74±0.99; P=0.08).

Accordingly, inability to exercise (nominal variable: yes/no) and hospitalization rate (ordinal variable: number of hospitalizations in the year preceding study inclusion) were associated with higher mortality (Table 2). Although the proportion of patients on β-blocker therapy was significantly higher among survivors (Table 1), no association was found between the use of β-blockers and survival (P>0.05).

ROC curve analysis [area under the curve (95% CI) =0.794 (0.639–0.904); P<0.001] showed absence of hospitalizations as having a 100% sensitivity and ≥2 hospitalizations/year with 91% of specificity to predict mortality.
The present study suggests that the history of previous COPD and/or CHF-related hospitalizations and clinical judgment of exercise incapacity to perform an exercise test may be potential predictors of future risk of death in patients with COPD plus CHF coexistence. Classical parameters of lung and heart function, as well as dyspnea and clinical functional capacity, were not associated with mortality in this group. Of particular clinical relevance, ≥2 hospitalizations in the preceding year before study inclusion were highly specific for a bad outcome (just 9% of false positive).

There are several therapeutic options to improve survival in each disease on isolation. The main challenge is to improve their

### Table 1. Clinical and functional baseline parameters of the overlap chronic obstructive pulmonary disease + chronic heart failure group according vital status during the follow-up period

<table>
<thead>
<tr>
<th>Survival</th>
<th>No (n = 7)</th>
<th>Yes (n = 34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>69.6 ± 13.1</td>
<td>66.9 ± 11.1</td>
</tr>
<tr>
<td>Male</td>
<td>3 (43)</td>
<td>25 (74)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.3 ± 7.4</td>
<td>25.7 ± 5.3</td>
</tr>
<tr>
<td>mMRC dyspnea</td>
<td>2.5 ± 1.4</td>
<td>1.8 ± 1.4</td>
</tr>
<tr>
<td>NYHA</td>
<td>2.0 ± 1.0</td>
<td>2.0 ± 0.8</td>
</tr>
</tbody>
</table>

### Etiology

- Ischemic cardiomyopathy
- Idiopathic cardiomyopathy
- Hypertensive cardiomyopathy
- Alcoholic cardiomyopathy
- Valvular heart disease
- Post-chemotherapy cardiomyopathy
- Two or more etiologies

### Cardiovascular risk factors

- Smoking history, pack-years (% current smokers)
- Hypertension
- Coronary disease
- Diabetes
- Stroke
- Peripheral vascular disease

### Other conditions

- Cancer

### Charlson comorbidity index

- Low (1–2)
- Moderate (3–4)
- High (≥5)

### Treatment

- ACE inhibitor
- β-Blocker
- Angiotensin II receptor antagonist
- Mineralocorticoid receptor antagonist
- Diuretic
- Statin
- Digitalis
- Inhaled corticosteroid
- Short-acting bronchodilator

### Post-bronchodilator lung function

- FEV1 (L (% pred))
- FVC (L (% pred))
- FEV1/FVC (%)

### Echocardiography

- LVEF (%)
- PSAP (mmHg)

### Table 1. (Continued)

<table>
<thead>
<tr>
<th>Survival</th>
<th>No (n = 7)</th>
<th>Yes (n = 34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LABA</td>
<td>4 (57)</td>
<td>14 (41)</td>
</tr>
<tr>
<td>LAMA</td>
<td>7 (100)</td>
<td>1 (3)</td>
</tr>
</tbody>
</table>

- FEV1 (L (% pred))
- FVC (L (% pred))
- FEV1/FVC (%)

<table>
<thead>
<tr>
<th>Survival</th>
<th>No (n = 7)</th>
<th>Yes (n = 34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEF (%)</td>
<td>34 ± 10</td>
<td>30 ± 9</td>
</tr>
<tr>
<td>PSAP (mmHg)</td>
<td>39 ± 10</td>
<td>43 ± 14</td>
</tr>
</tbody>
</table>

### Table 2. Mortality prediction based on univariate logistic regression analyses

<table>
<thead>
<tr>
<th>Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
</tr>
<tr>
<td>mMRC dyspnea score</td>
</tr>
<tr>
<td>NYHA functional class</td>
</tr>
<tr>
<td>β-Blocker treatment</td>
</tr>
<tr>
<td>FEV1 (% pred)</td>
</tr>
<tr>
<td>FVC (% pred)</td>
</tr>
<tr>
<td>FEV1/FVC (%)</td>
</tr>
<tr>
<td>LVEF (%)</td>
</tr>
<tr>
<td>Inability for exercise testing</td>
</tr>
<tr>
<td>Hospitalization rate</td>
</tr>
</tbody>
</table>

CI = confidence interval; BMI = body mass index; mMRC = modified Medical Research Council dyspnea scale; NYHA = New York Heart Association Functional Classification; ACE = angiotensin-converting enzyme; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist; FEV1 = forced expired volume in 1 s; FVC = forced vital capacity; % pred = % of predicted; LVEF = left ventricular ejection fraction; PSAP = pulmonary systolic arterial pressure.

*P < 0.05.

### Discussion

The present study suggests that the history of previous COPD and/or CHF-related hospitalizations and clinical judgment of exercise incapacity to perform an exercise test may be potential predictors of future risk of death in patients with COPD plus CHF coexistence. Classical parameters of lung and heart function, as well as dyspnea and clinical functional capacity, were not associated with mortality in this group. Of particular clinical relevance, >2 hospitalizations in the preceding year before study inclusion were highly specific for a bad outcome (just 9% of false positive).

There are several therapeutic options to improve survival in each disease on isolation. The main challenge is to improve their...
utilization (Bender, 2014; Thorvaldsen et al., 2016). Some of these options, however, are expensive and of limited availability. Therefore, optimal identification of patients with increased risk of mortality or more suitable for a given intervention is of clear relevance (DeCamp et al., 2006; Lund et al., 2010). Notwithstanding, despite the growing aged population with the coexistence of both conditions (Fabbri et al., 2008; Rutten, 2013) and the reciprocal modulation of the diseases (Apostolo et al., 2015; Arbex et al., 2016), prognostic studies in the context of coexistent diseases are still scarce in the literature.

Interestingly, clinical and physiological parameters currently incorporated in several prognostic models recommended by specific COPD (Vogelmeier et al., 2017) and CHF (Yancy et al., 2013) guidelines were not associated with mortality. Although our best efforts to include the highest number of patients, our sample is underpowered to detect some associations between baseline parameters and mortality depending on the magnitude of the association (Hsieh, 1989). Confirming the diagnosis of both diseases needs complementary exams and the usual more severe clinical condition of these patients challenges the recruitment and follow-up for research. Accordingly, the average sample size of the majority of previous studies in the scarce literature available is similar to ours (Rutten et al., 2005; Beghe et al., 2013; Boschetto et al., 2013; Alencar et al., 2016). Even though, some statistically significant associations were found. The small number of deaths in the present study, however, precludes the performance of multivariate logistic regression analyses evaluating the independent significance of these associations. We can verify, on the other hand, that these currently observed significant predictors have higher odds ratio to predict mortality than those without statistical significance (Hsieh, 1989) and represent potential candidates to refine survival models of COPD + CHF in next studies. If our results are confirmed in the future, from a clinical perspective, overlap patients presenting hospitalization(s) in the previous year and/or a clinical judgment of incapacity to perform an exercise test may be at high risk and considered potential candidates for add-on therapeutic options or palliation. For those able to exercise and, when available, a CPET could be performed in order to improve risk stratification (Mancini et al., 1991; Oga et al., 2003; Poggio et al., 2010; Alencar et al., 2016; Neder et al., 2016).

Finally, it was shown that even in stable outpatient subjects, the coexistence of COPD and CHF should not be neglected (14% in the present sample). Patients initially diagnosed with one disorder even without clear evidence of the other may pass unnoticed, once they share clinical, etiological and epidemiological factors (Fabbri et al., 2008; Rutten, 2013). Notwithstanding, the mortality rate was not significantly different among the groups (COPD = 11%; CHF = 12%; overlap = 17%), possibly related to an underpowered sample (Macchia et al., 2012).

To conclude, hospitalization rate and clinical judgment of incapacity to perform an exercise test were the unique investigated parameters associated with mortality in our sample. Nevertheless, the lack of association between other variables and mortality may be resultant of an underpowered sample.

Acknowledgments. The authors are thankful to all healthcare professionals who work in the care of COPD and heart failure patients in the outpatient clinic of Hospital de Clínicas de Porto Alegre (HCPA) and to the research unit (Grupo de Pesquisa e Pós-Graduação; GPPG) of HCPA due to statistical analysis support.

Financial Support. This study was funded by Fundo de Incentivo à Pesquisa do Hospital de Clínicas de Porto Alegre (FIP-E-HCPA) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CAPES, Brazil).

Conflicts of Interest. The authors report no conflicts of interest.

References


